TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07869225: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered EQ504 in Healthy Volunt

Sponsor: Equillium · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07869225 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07869225 Rescue Dossier →